Detalhe da pesquisa
1.
A 61-year-old patient with Crohn's disease and severe postoperative recurrence responding to JAK inhibitor ruxolitinib for polycythemia vera treatment.
Gastroenterol Hepatol
; 45 Suppl 1: 16-17, 2022 04.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-34284085
2.
Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
J Crohns Colitis
; 18(1): 65-74, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37522878
3.
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Therap Adv Gastroenterol
; 17: 17562848231221713, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38187926
4.
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
J Crohns Colitis
; 17(1): 83-91, 2023 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913456
5.
Endoscopic treatment (endoscopic balloon dilation/self-expandable metal stent) vs surgical resection for the treatment of de novo stenosis in Crohn's disease (ENDOCIR study): an open-label, multicentre, randomized trial.
Trials
; 24(1): 432, 2023 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37365665
6.
Low complement levels and opsonic activity in hepatic hydrothorax: its relationship with spontaneous bacterial empyema.
J Clin Gastroenterol
; 36(1): 75-7, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12488714